Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

OBJECTIVE To test whether rs1990622 (TMEM106B) is associated with age at onset (AAO) in granulin (GRN) mutation carriers and with plasma GRN levels in mutation carriers and healthy, elderly individuals. Rs1990622 (TMEM106B) was identified as a risk factor for frontotemporal lobar degeneration with TAR DNA-binding protein inclusions (FTLD-TDP) in a recent genome-wide association. DESIGN Rs1990622 was genotyped in GRN mutation carriers and tested for association with AAO using the Kaplan-Meier method and a Cox proportional hazards model. SETTING Alzheimer's Disease Research Center. Subjects  We analyzed 50 affected and unaffected GRN mutation carriers from 4 previously reported FTLD-TDP families (HDDD1, FD1, HDDD2, and the Karolinska family). The GRN plasma levels were also measured in 73 healthy, elderly individuals. MAIN OUTCOME MEASURES Age at onset and GRN plasma levels. RESULTS The risk allele of rs1990622 was associated with a mean decrease of the AAO of 13 years (P = 9.9 × 10(-7)) and with lower plasma GRN levels in both healthy older adults (P = 4 × 10(-4)) and GRN mutation carriers (P = .0027). Analysis of the HapMap database identified a nonsynonymous single-nucleotide polymorphism rs3173615 (T185S) in perfect linkage disequilibrium with rs1990622. CONCLUSIONS The association of rs1990622 with AAO explains, in part, the wide range in the AAO of disease among GRN mutation carriers. We hypothesize that rs1990622 or another variant in linkage disequilibrium could act in a manner similar to APOE in Alzheimer disease, increasing risk for disease in the general population and modifying AAO in mutation carriers. Our results also suggest that genetic variation in TMEM106B may influence risk for FTLD-TDP by modulating secreted levels of GRN.

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  A. Fagan,et al.  SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease , 2010, PLoS genetics.

[3]  Alzheimer's Disease Neuroimaging Initiative,et al.  Validating predicted biological effects of Alzheimer's disease associated SNPs using cerebrospinal fluid biomarker levels , 2010, Alzheimer's & Dementia.

[4]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[5]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[6]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[8]  M. J. Fresnadillo Martínez,et al.  Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions , 2010, Nature Genetics.

[9]  Z. Arvanitakis.  Update on Frontotemporal Dementia , 2010, The neurologist.

[10]  N. Bresolin,et al.  Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease , 2009, Journal of the Neurological Sciences.

[11]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[12]  K. Sleegers,et al.  Serum biomarker for progranulin‐associated frontotemporal lobar degeneration , 2009, Annals of neurology.

[13]  T. Bird.  Progranulin plasma levels in the diagnosis of frontotemporal dementia. , 2009, Brain : a journal of neurology.

[14]  A. Fagan,et al.  Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.

[15]  R. Petersen,et al.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members , 2009, Brain : a journal of neurology.

[16]  C. Graff,et al.  Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family , 2008, Alzheimer's & Dementia.

[17]  G. Binetti,et al.  Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration , 2008, Neurology.

[18]  A. Fagan,et al.  Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.

[19]  J. Morris,et al.  Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia , 2008, Human mutation.

[20]  D. Stephan,et al.  A survey of genetic human cortical gene expression , 2007, Nature Genetics.

[21]  D. Geschwind,et al.  Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative , 2007, The Lancet Neurology.

[22]  J. Morris,et al.  Neuropathologic Heterogeneity in HDDD1: A Familial Frontotemporal Lobar Degeneration With Ubiquitin-positive Inclusions and Progranulin Mutation , 2007, Alzheimer disease and associated disorders.

[23]  S. Melquist,et al.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.

[24]  J. Morris,et al.  HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin , 2006, Annals of neurology.

[25]  Joaquín Dopazo,et al.  PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes , 2006, Nucleic Acids Res..

[26]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[27]  D. Thomas,et al.  Case‐sibling gene‐association studies for diseases with variable age at onset , 2004, Statistics in medicine.

[28]  M. Orozco,et al.  Triplex-forming oligonucleotide target sequences in the human genome. , 2004, Nucleic acids research.

[29]  Kenneth S. Kosik,et al.  Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred , 2003 .

[30]  Zuzana Dobbie,et al.  Processing of gene expression data generated by quantitative real-time RT-PCR. , 2002, BioTechniques.

[31]  Hongyu Zhao.  Family-based association studies , 2000, Statistical methods in medical research.

[32]  B Langholz,et al.  Testing linkage disequilibrium in sibships. , 2000, American journal of human genetics.

[33]  B. Tycko,et al.  No association between a presenilin 1 polymorphism and Alzheimer disease. , 2000, Archives of neurology.

[34]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[35]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[36]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[37]  A. Fagan,et al.  Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. , 2010, Journal of Alzheimer's disease : JAD.

[38]  G. Bedoya,et al.  Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. , 2003, Annals of neurology.